Investment Thesis
Stoke Therapeutics demonstrates early revenue traction (+404.5% YoY) and maintains a fortress balance sheet with zero debt and $155.7M cash, but faces a critical challenge: annual operating losses of $53.4M with only ~2.5 years of cash runway at current burn rates. The company must achieve significant revenue inflection or major profitability improvements within this window, or face forced equity dilution and potential strategic alternatives.
Strengths
- Exceptional revenue growth (404.5% YoY) indicating product market traction
- Fortress balance sheet with zero debt, $394.9M equity, and 8.99x current ratio providing financial flexibility
- Adequate near-term liquidity (~$155.7M cash) with low leverage profile typical of well-capitalized biotech
Risks
- Severe unprofitability with -$802.7% net margin and -$60.6M annual operating cash burn limiting runway to ~2.5 years
- Limited revenue base ($6.2M) insufficient to offset operating expenses, requiring major scale-up or path to profitability is unclear
- Likely future capital dilution needed to extend runway, absent substantial revenue inflection or strategic partnerships reducing burn rate
Key Metrics to Watch
- Operating cash burn rate trend and months of cash runway remaining
- Revenue growth trajectory and gross margin as product scales
- Achievement of clinical/regulatory milestones that could trigger partnerships or reduce cash burn requirements
Financial Metrics
Revenue
6.2M
Net Income
-50.0M
EPS (Diluted)
$-0.79
Free Cash Flow
-60.9M
Total Assets
443.3M
Cash
155.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-857.6%
Net Margin
-802.7%
ROE
-12.7%
ROA
-11.3%
FCF Margin
-978.2%
Balance Sheet & Liquidity
Current Ratio
8.99x
Quick Ratio
8.99x
Debt/Equity
0.00x
Debt/Assets
10.9%
Interest Coverage
-2,322.52x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:15:10.545241 |
Data as of: 2026-03-31 |
Powered by Claude AI